Top Searched Resources

CROI 2017: Bone Density Improves in People Who Switch from Tenofovir DF to Tenofovir Alafenamide

After 3 years, tenofovir alafenamide (TAF) for first-line HIV treatment was better at suppressing viral load and safer for the bones and kidneys than the older tenofovir disoproxil fumarate (TDF), researchers reported at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) …

A LOOK INTO THE GREY ZONE: AGEING WITH HIV

Ageing with HIV, can be both a celebration and a concern. A celebration because effective HIV treatments have given life-years back to all people on effective treatment; but a concern since people are now moving into older age with HIV and …

Give the Flu the Flick

Yes folks, it’s that time of year again to get flu vaccinated and build up our winter defences against the debilitating effects of influenza. The official flu season typically spans from May to October each year. Flu vaccination is available from …

NEW LONG ACTING HIV DRUG CLASS ON THE HORIZON – CAPSID INHIBITORS

Capsid assembly is the step in the HIV lifecycle where the virus develops a cone-shaped core (capsid) particle, which contains or encloses the viral genetic blueprint (genome), inside a maturing infectious virion. It consists of a protein envelop membrane which protects …

Bictegravir – A new Integrase Inhibitor in the pipeline

Bictegravir matches dolutegravir for first-line treatment in Phase 2 studies Paul Sax at CROI 2017. Photo by Liz Highleyman, hivandhepatitis.com Bictegravir, an investigational new integrase inhibitor, was highly potent, well tolerated and worked as well as dolutegravir (Tivicay – an existing …

Doravirine – a new NNRTI (Non-Nuke) option on the horizon

Kathleen Squires at CROI 2017. Photo by Liz Highleyman, hivandhepatitis.com Doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that reduced HIV viral load as well as boosted darunavir (a Protease Inhibitor) in a phase 3 clinical trial of people starting …